. 2020 Jun 10;5:89. doi: 10.1038/s41392-020-0190-2

Table 2.

Potential drugs and vaccines against three coronaviruses

		SARS-CoV	MERS-CoV	SARS-CoV-2	References
Potential virally targeted agents	Potential drugs inhibiting cell entry	CP-1 Griffithsin CSS-2,3,4,5	HR2P sDPP4 7D10	EK1 EK1C4 Griffithsin CSS-2,3,4,5	^{34,100,111,113,115,164,165}
	nAbs	CR3022 m396 80R 33G4	m336 MERS-4 MERS-27	CR3022	^160–163
	Protease inhibitors	Remdesivir Ribavirin Galidesivir Lopinavir Bananins 5-Hydroxychromone derivatives Disulfiram	Favipiravir Ribavirin Penciclovir Remdesivir Lopinavir Ritonavir Darunavir	Remdesivir Ribavirin Galidesivir Lopinavir Ritonavir Camostat Mesylate	^{34,111,121,122}
	Viral RNA synthesis blockers		Remdesivir		¹¹⁷
		Ribavirin Galidesivir (BCX4430)		Favipiravir (T-705)	^{14,34,41,108,115,122,126}
	Other agents		Convalescent plasma		¹⁰⁸
		Corticosteroids 6-mercaptopurine-6-thioguaninet IFNα Antiviral treatments	IFNα Antimicrobial peptides (AMPs) Mycophenolic acid Nitazoxamide Mycophenolate mofetil (MMF)		^{14,19,38,41,59,122,133,134}
Potential host-targeted agents		Pegylated interferon alfa-2a; Pegylated interferon alfa-2b; Metformin; Glitazones; Fibrates; Sartans; Atorvastin; nutrient supplements; biologics; cellular therapies; IFNα together with immunoglobulins or thymosins;			^34,39,136
		Cathepsin B cathepsinL Camostat		Chloroquine	^{14,34,100,134}
Spike-based vaccines		A recombinant fusion protein (designated RBD-Fc) containing 193-amino acid RBD and a human IgG1 Fc fragment	Simian adenovirus vector vaccine (ChAdOx1);an Ad vector encoding MERS-CoV S1 extracellular domain (Ad5.MERS-S1);an RABV vector encoding S1 elicit antibody;RBD-based vaccines		^{61,138,139,140}